PHI secures a loan facility of in total SEK 7 million
Phase Holographic Imaging PHI AB ("PHI" or the "Company") announces that the Company has secured a loan facility of in total SEK 7 million from Bizcap AB, and from that loan facility decided to draw a tranche of SEK 4.5 million.
Loan facility
PHI has signed an agreement with Bizcap AB regarding a loan facility of in total SEK 7 million, making it possible for PHI to draw two loan tranches of SEK 4.5 million and SEK 2.5 million respectively. PHI has decided to draw upon a first tranche of SEK 4.5 million. The loan facility has a setup fee of 5 percent and the activated loan runs with an interest rate of 1.5 percent per month, with a maturity date on the 31st of October 2024. PHI can repay the loan and interest at any time before the maturity date.
The loan facility has been secured in order to provide PHI with working capital and act on the current momentum in the Company.
Financial advisor
Sedermera Corporate Finance AB has been the Company's financial advisor in connection with the loan financing.
This disclosure contains information that Phase Holographic is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 17-05-2024 08:10 CET.
For additional information, please contact:
Patrik Eschricht
E-mail: ir@phiab.com
Web: www.phiab.com – Live cell imaging & analysis
About PHI
Phase Holographic Imaging (PHI) is a medical technology company that develops and markets its non-invasive time-lapse imaging instruments for long-term quantitative analysis of living cells. The foundation of PHI’s current commercial HoloMonitor® products is Quantitative Phase Imaging (QPI) technology — an innovative approach to cell quality evaluation. QPI offers detailed analysis of cell characteristics without harming the cells, avoiding the limitations of traditional measurement methods. PHI is actively focusing on business development to expand from pre-clinical research to the clinical market and the emerging regenerative medicine field. PHI envisions transforming live cell analysis and establishing QPI as a standard for cell quality control, making future cell therapies safe, affordable, and accessible for patients. PHI is based in Lund, Sweden, Boston, MA and Winston-Salem, NC.